Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA-GPRC5D CAR-T in R/R Multiple Myeloma
NCT05998928Phase 2Recruiting
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Ori-CAR-002 in multiple myeloma (MM). Primary endpoint: Incidence of Treatment-related Adverse Events at 2 years. Started Jul 2023; status: recruiting.
02
Drugs
Ori-CAR-002
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05998928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05998928.